×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BNTC – benitec biopharma inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BNTC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/10
07:37 am
bntc
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc
Medium
Report
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc
3/10
07:00 am
bntc
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc
Low
Report
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc
3/9
04:05 pm
bntc
Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by TD Cowen.
3/9
12:42 pm
bntc
Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
Low
Report
Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
3/9
07:32 am
bntc
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference [Yahoo! Finance]
Low
Report
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference [Yahoo! Finance]
3/9
07:00 am
bntc
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Medium
Report
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
2/23
07:00 am
bntc
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Low
Report
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
2/12
08:30 am
bntc
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Medium
Report
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/20
04:03 pm
bntc
Form 10-K/A Benitec Biopharma Inc. For: Jun 30
Low
Report
Form 10-K/A Benitec Biopharma Inc. For: Jun 30
2/12
08:10 am
bntc
Form 8-K Benitec Biopharma Inc. For: Feb 12
Medium
Report
Form 8-K Benitec Biopharma Inc. For: Feb 12
2/12
08:08 am
bntc
Form 10-Q Benitec Biopharma Inc. For: Dec 31
Medium
Report
Form 10-Q Benitec Biopharma Inc. For: Dec 31
2/11
06:05 am
bntc
Form EFFECT Benitec Biopharma Inc.
Low
Report
Form EFFECT Benitec Biopharma Inc.
2/11
06:00 am
bntc
Form 424B3 Benitec Biopharma Inc.
Low
Report
Form 424B3 Benitec Biopharma Inc.
1/30
04:03 pm
bntc
Form S-3 Benitec Biopharma Inc.
Low
Report
Form S-3 Benitec Biopharma Inc.
1/29
11:34 am
bntc
Form SCHEDULE 13G/A Benitec Biopharma Inc. Filed by: FRANKLIN RESOURCES INC
Low
Report
Form SCHEDULE 13G/A Benitec Biopharma Inc. Filed by: FRANKLIN RESOURCES INC
1/26
04:10 pm
bntc
Form 4 Benitec Biopharma Inc. For: Jan 22 Filed by: Mates Sharon
Low
Report
Form 4 Benitec Biopharma Inc. For: Jan 22 Filed by: Mates Sharon
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/20
BENITEC BIOPHAR/S (NASDAQ: BNTC) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $14.00 price target on the stock.
109.0%
4/14 Form 25-NSE Benitec Biopharma LTD/AD Filed by: The Nasdaq Stock Market LLC 33.9%
7/31 ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report 28.8%
3/26 Benitec Announces Results of Scheme Meeting 11.9%
4/17 Form EFFECT Benitec Biopharma LTD/AD 6.6%
10/31 Appendix 4C: Quarterly Cash Flow Report 5.2%
9/16 Benitec Biopharma Provides Update on BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Program 1.6%
4/27 Form 3 Benitec Biopharma Inc. For: Apr 15 Filed by: SOON-SHIONG PATRICK 1.3%
4/14 Form 25-NSE Benitec Biopharma LTD/AD Filed by: The Nasdaq Stock Market LLC 33.9%
7/31 ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report 28.8%
3/26 Benitec Announces Results of Scheme Meeting 11.9%
4/17 Form EFFECT Benitec Biopharma LTD/AD 6.6%
10/31 Appendix 4C: Quarterly Cash Flow Report 5.2%
9/16 Benitec Biopharma Provides Update on BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Program 1.6%
4/27 Form 3 Benitec Biopharma Inc. For: Apr 15 Filed by: SOON-SHIONG PATRICK 1.3%
TOP News Decliners
6/6
Update on Oculopharyngeal Muscular Dystrophy Program
-34.2%
9/19 Benitec Biopharma to present at Ladenburg Thalmann 2019 Healthcare Conference -14.0%
11/27 ASX/NASDAQ ANNOUNCEMENT: Re-domiciliation to the United States -10.2%
4/3 Form 6-K Benitec Biopharma LTD/AD For: Apr 03 -7.5%
1/31 Appendix 4C: Quarterly Cash Flow Report -6.7%
4/27 Form 3 Benitec Biopharma Inc. For: Apr 15 Filed by: Boston Megan -1.6%
9/19 Benitec Biopharma to present at Ladenburg Thalmann 2019 Healthcare Conference -14.0%
11/27 ASX/NASDAQ ANNOUNCEMENT: Re-domiciliation to the United States -10.2%
4/3 Form 6-K Benitec Biopharma LTD/AD For: Apr 03 -7.5%
1/31 Appendix 4C: Quarterly Cash Flow Report -6.7%
4/27 Form 3 Benitec Biopharma Inc. For: Apr 15 Filed by: Boston Megan -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: